<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Public Health Surveill</journal-id><journal-id journal-id-type="publisher-id">publichealth</journal-id><journal-id journal-id-type="index">9</journal-id><journal-title>JMIR Public Health and Surveillance</journal-title><abbrev-journal-title>JMIR Public Health Surveill</abbrev-journal-title><issn pub-type="epub">2369-2960</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v11i1e65783</article-id><article-id pub-id-type="doi">10.2196/65783</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Impact of the National Essential Public Health Service Package on Blood Pressure Control in Chinese People With Hypertension: Retrospective Population-Based Longitudinal Study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wei</surname><given-names>Feiran</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ge</surname><given-names>You</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names>Han</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names>Yuan</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><institution>School of Public Health, Southeast University</institution><addr-line>Nanjing</addr-line><country>China</country></aff><aff id="aff2"><institution>Department of Infectious Disease, The Second Hospital of Nanjing</institution><addr-line>Nanjing</addr-line><country>China</country></aff><aff id="aff3"><institution>Institute for Chronic Disease Management</institution><addr-line>Jining No. 1 People&#x2019;s Hospital, 0802 Huoju</addr-line><addr-line>Jining</addr-line><country>China</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Mavragani</surname><given-names>Amaryllis</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Sanchez</surname><given-names>Travis</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Wang</surname><given-names>Wei</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Ren</surname><given-names>Yongcheng</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Yuan Liu, MSc, Institute for Chronic Disease Management, Jining No. 1 People&#x2019;s Hospital, 0802 Huoju, Jining, 272000, China, +8619853782628; <email>yuan_liu_1@126.com</email></corresp><fn fn-type="equal" id="equal-contrib1"><label>*</label><p>these authors contributed equally</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>6</day><month>2</month><year>2025</year></pub-date><volume>11</volume><elocation-id>e65783</elocation-id><history><date date-type="received"><day>26</day><month>08</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2024</year></date></history><copyright-statement>&#x00A9; Feiran Wei, You Ge, Han Li, Yuan Liu. Originally published in JMIR Public Health and Surveillance (<ext-link ext-link-type="uri" xlink:href="https://publichealth.jmir.org">https://publichealth.jmir.org</ext-link>), 6.2.2025. </copyright-statement><copyright-year>2025</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://publichealth.jmir.org">https://publichealth.jmir.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://publichealth.jmir.org/2025/1/e65783"/><abstract><sec><title>Background</title><p>The National Essential Public Health Service Package (NEPHSP) was launched in 2009 to tackle poor blood pressure control in Chinese people with hypertension; however, it&#x2019;s effect is still unclear.</p></sec><sec><title>Objective</title><p>In a retrospective population-based longitudinal study, we aimed to evaluate effect of the NEPHSP on blood pressure control.</p></sec><sec sec-type="methods"><title>Methods</title><p>A total of 516,777 patients registered in the NEPHSP were included. The blood pressure control data were assessed based on the Residence Health Record System dataset. We longitudinally evaluated the effects of the NEPHSP on blood pressure control by analyzing changes in blood pressure at quarterly follow-ups. Both the degree and trend of the blood pressure changes were analyzed. We conducted stratified analysis to explore effects of the NEPHSP on blood pressure control among subgroups of participants with specific characteristics.</p></sec><sec sec-type="results"><title>Results</title><p>The mean baseline systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 147.12 (SD 19.88) mm Hg and 85.11 (SD 11.79) mm Hg, respectively. The control rates of baseline SBP and DBP were 39.79% (205,630/516,777) and 69.21% (357,685/516,777). Compared to baseline, the mean SBP decreased in each quarter by 5.06 mm Hg (95% CI &#x2212;5.11 to &#x2212;5.00; <italic>P</italic>&#x003C;.001), 6.69 mm Hg (95% CI; &#x2212;6.74 to &#x2212;6.63; <italic>P</italic>&#x003C;.001), 10.30 mm Hg (95% CI &#x2212;10.34 to &#x2212;10.23; <italic>P</italic>&#x003C;.001), and 6.63 mm Hg (95% CI &#x2212;6.68 to &#x2212;6.57; <italic>P</italic>&#x003C;.001). The SBP control rates increased in each quarter to 53.12% (274,493/516,777; &#x03B2; coefficient=0.60, 95% CI 0.59-0.61; <italic>P</italic>&#x003C;.001), 56.61% (292,537/516,777; &#x03B2; coefficient=0.76, 95% CI 0.75-0.77; <italic>P</italic>&#x003C;.001), 63.4% (327,648/516,777; &#x03B2; coefficient=1.08, 95% CI 1.07-1.09; <italic>P</italic>&#x003C;.001), and 55.09% (284,711/516,777; &#x03B2; coefficient=0.69, 95% CI 0.68-0.70; <italic>P</italic>&#x003C;.001). Compared to baseline, the mean DBP decreased in each quarter by 1.75 mm Hg (95% CI &#x2212;1.79 to &#x2212;1.72; <italic>P</italic>&#x003C;.001), 2.64 mm Hg (95% CI &#x2212;2.68 to &#x2212;2.61; <italic>P</italic>&#x003C;.001), 4.20 mm Hg (95% CI &#x2212;4.23 to &#x2212;4.16; <italic>P</italic>&#x003C;.001), and 2.64 mm Hg (95% CI &#x2212;2.68 to &#x2212;2.61; <italic>P</italic>&#x003C;.001). DBP control rates increased in each quarter to 78.11% (403,641/516,777; &#x03B2; coefficient=0.52, 95% CI 0.51-0.53; <italic>P</italic>&#x003C;.001), 80.32% (415,062/516,777; &#x03B2; coefficient=0.67, 95% CI 0.66-0.68; <italic>P</italic>&#x003C;.001), 83.17% (429,829/516,777; &#x03B2; coefficient=0.89, 95% CI 0.88-0.90; <italic>P</italic>&#x003C;.001), and 79.47% (410,662/516,777; &#x03B2; coefficient=0.61, 95% CI 0.60-0.62; <italic>P</italic>&#x003C;.001). The older age group had a larger decrease in their mean SBP (&#x03B2; coefficient=0.87, 95% CI 0.85-0.90; <italic>P</italic>&#x003C;.001) and a larger increase in SBP control rates (&#x03B2; coefficient=0.054, 95% CI 0.051-0.058; <italic>P</italic>&#x003C;.001). The participants with cardiovascular disease (CVD) had a smaller decrease in their mean SBP (&#x03B2; coefficient=&#x2212;0.38, 95% CI &#x2212;0.41 to &#x2212;0.35; <italic>P</italic>&#x003C;.001) and smaller increase in SBP control rates (&#x03B2; coefficient=&#x2212;0.041, 95% CI &#x2212;0.045 to &#x2212;0.037; <italic>P</italic>&#x003C;.001) compared to the blood pressure of participants without CVD.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The NEPHSP was effective in improving blood pressure control of Chinese people with hypertension. Blood pressure control of older individuals and those with CVD need to be intensified.</p></sec></abstract><kwd-group><kwd>hypertension</kwd><kwd>primary care</kwd><kwd>public health</kwd><kwd>blood pressure control</kwd><kwd>cardiovascular disease</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The Global Burden of Disease Study reported that cardiovascular diseases (CVDs) are the leading noncommunicable disease contributing to the increase in disease-adjusted life years in China [<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref3">3</xref>]. Hypertension, the major modifiable risk factor for CVDs, is prevalent in China [<xref ref-type="bibr" rid="ref4">4</xref>-<xref ref-type="bibr" rid="ref12">12</xref>]. According to the data of a recent survey conducted nationwide, the prevalence of hypertension was 54.7% among Chinese adults over 18 years old, and reportedly, merely 60.1% of Chinese adults with hypertension accepted antihypertensive treatments [<xref ref-type="bibr" rid="ref13">13</xref>]. The low hypertension treatment rate has led to a suboptimal control of blood pressure among Chinese adults with hypertension [<xref ref-type="bibr" rid="ref13">13</xref>]. Merely 7.2% of Chinese adults with hypertension had their blood pressures under control [<xref ref-type="bibr" rid="ref13">13</xref>].</p><p>To tackle the poor hypertension control and growing burden of CVDs, the Chinese government launched the National Essential Public Health Service Package (NEPHSP) in 2009 [<xref ref-type="bibr" rid="ref14">14</xref>]. The NEPHSP was a set of public health services which were available for all community-dwelling residents [<xref ref-type="bibr" rid="ref14">14</xref>-<xref ref-type="bibr" rid="ref18">18</xref>]. The public health services contain 4 modules, which are screening, monitoring, regular follow-up, and individualized interventions for hypertension control. The 4 modules were provided by primary health care professionals [<xref ref-type="bibr" rid="ref14">14</xref>-<xref ref-type="bibr" rid="ref18">18</xref>]. NEPHSP registration has been continuously expanded since it was launched in 2009 [<xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref18">18</xref>]. A total of 109 million Chinese adults diagnosed with hypertension registered with the NEPHSP from 2009 to 2019 [<xref ref-type="bibr" rid="ref14">14</xref>]. The government investment increased from 15 to 84 RMB (US $2.05 to US $11.46) per person annually [<xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref18">18</xref>]. Because of the registration expansion and investment increase for the NEPHSP, the proportion of Chinese adult with hypertension who accepted antihypertensive treatment increased by 59.58% from 2009 to 2019 [<xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref18">18</xref>].</p><p>Although the registration expansion and investment increase for the NEPHSP improved the hypertension treatment rate, the NEPHSP lacks quality-oriented evaluations, which leads to an uncertainty whether the NEPHSP is effective for blood pressure control [<xref ref-type="bibr" rid="ref14">14</xref>-<xref ref-type="bibr" rid="ref18">18</xref>]. Furthermore, research demonstrating the effectiveness of the NEPHSP for blood pressure control in Chinese adults with hypertension is lacking [<xref ref-type="bibr" rid="ref14">14</xref>-<xref ref-type="bibr" rid="ref18">18</xref>]. To fulfill the research gap, this study aimed to explore effect of the NEPHSP on blood pressures control of Chinese adult with hypertension.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study Design</title><p>This study was designed as longitudinal study to evaluate effect of the NEPHSP intervention on blood pressure control. The longitudinal study observed changes in the health status and clinical indicators of individuals who accepted treatment in a period of time, in order to explore the association between treatment and disease control [<xref ref-type="bibr" rid="ref19">19</xref>-<xref ref-type="bibr" rid="ref22">22</xref>]. Longitudinal studies have been commonly used in clinical research to evaluate the effects of treatment [<xref ref-type="bibr" rid="ref19">19</xref>-<xref ref-type="bibr" rid="ref22">22</xref>]. In this longitudinal study, we repetitively measured the blood pressure in participants who accepted hypertension care services offered by the NEPHSP in each quarter of 2023. All participants had a recorded blood pressure measurement prior to joining the NEPHSP in 2022. With the baseline outcomes in 2022 as the control, the degree and trend of the blood pressure changes after receiving NEPHSP in 2023 were analyzed longitudinally.</p><p>The data in this study were extracted from the Residence Health Record System, which is an electronic health record system built to recording demographic and health information of people registering with the NEPHSP [<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref>]. This study used data of the Residence Health Record System built in Jining City, which is a national pilot city of the Chronic Disease Comprehensive Prevention and Control programs and is located in eastern China.</p></sec><sec id="s2-2"><title>Study Participants</title><p>We analyzed data from the NEPHSP participants from 1593 primary care institutions in the 9 districts in Jining City. Eligibility criteria were (1) individuals registering with the NEPHSP as a patient with hypertension, (2) individuals who had baseline records of health examinations in 2022, (3) individuals who accepted health care services offered by the NEPHSP in 2023, and (4) individuals who had records for quarterly follow-ups conducted in 2023. The flowchart of participant inclusion is described in <xref ref-type="fig" rid="figure1">Figure 1</xref>.</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>The flowchart of the participant inclusion. NEPHSP: National Essential Public Health Service Package.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v11i1e65783_fig01.png"/></fig></sec><sec id="s2-3"><title>Intervention</title><p>The NEPHSP was divided into 4 dimensions: screening, routine follow-ups, individualized interventions, and annual health examinations. The explicit flowchart of the NEPHSP is described in <xref ref-type="fig" rid="figure2">Figure 2</xref>.</p><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Flowchart of the NEPHSP. NEPHSP: National Essential Public Health Service Package.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v11i1e65783_fig02.png"/></fig><p>The screening was conducted at primary care institutions when community residents had an appointment with primary health care professionals. The criteria for a hypertension diagnosis were a systolic blood pressure (SBP) over 140 mm Hg or a diastolic blood pressure (DBP) over 90 mm Hg for 3 separate measurements on different days. The residents were invited to register with the NEPHSP if they were diagnosed with hypertension.</p><p>The routine follow-up contained 5 facets: (1) assessing emergency conditions, (2) evaluating hypertensive symptoms, (3) measuring blood pressure, (4) evaluating healthy behaviors, and (5) evaluating medication treatment regimens and compliance. Assessing emergency conditions was the first part of the routine follow-up. The participants would be referred to secondary or tertiary care settings if there were emergency conditions that were hard to tackle in primary care institutions. If no emergency conditions were identified, the remaining parts would be conducted. The regular follow-ups were provided quarterly.</p><p>The individualized interventions contained 3 components: medication treatment adjustment, referral channel to superior medical institutions, and healthy behavior changes. According to health conditions that were evaluated in the regular follow-ups, primary care professionals would make decisions on medication treatment adjustments for the participants. If the health issues could not be handled in primary care settings, the primary care professionals would transfer the patient to superior medical institutions. The explicit processes and criteria of medication treatment adjustment and referral were divided into 3 dimensions. First, if blood pressure was under control, there were no adverse drug reactions, and there was not an occurrence of comorbidities or an aggravation of comorbidities, the next follow-up appointments were made for the participants. Second, if blood pressures were uncontrolled or adverse drug reactions were identified, the primary health care professionals would adjust the antihypertensive medication regimens. The conditions of the participants would be re-evaluated within 2 weeks. Third, if the patients had refractory uncontrolled blood pressure, adverse drug reactions that could not be tackled in primary care settings, or an occurrence and aggravation of comorbidities, the primary health care professionals would refer the participants to secondary or tertiary care settings. The conditions of the participants would be re-evaluated within 2 weeks.</p><p>Changes in health behavior were available for all participants, and goal-setting was used to formulate their health behaviors. The primary health care professionals developed shared goals with the participants. The targets for changes in health behavior included medication treatment compliance, dietary changes and weight control, control of smoking and alcohol drinking, and exercise engagement. The achievements of the health behavior changes were evaluated at the routine follow-ups. Annual health examinations were available for all patients. The health examinations contained overall physical and bioclinical examinations, as well as lifestyle and medication treatment evaluations.</p></sec><sec id="s2-4"><title>Outcome Variables</title><p>We evaluated the impact of the NEPHSP on blood pressure control in Chinese patients with hypertension through changes in SBP and DBP and changes in the control rates of SBP and DBP. The control rates of SBP and DBP were the proportion of study participants whose SBP and DBP values were in the normal range, respectively. The normal range of SBP and DBP in the Chinese hypertension guideline is defined as &#x003C;140 mm Hg and &#x003C;90 mm Hg, respectively [<xref ref-type="bibr" rid="ref23">23</xref>].</p><p>We used the mean blood pressure values at baseline in 2022 and at 4 quarterly follow-up visits in 2023 to depict trends in blood pressure for the patients before and after receiving the NEPHSP services. The baseline values of SBP and DBP were averaged by the blood pressure measurements of the health examinations in 2022. The mean follow-up values of SBP and DBP were averaged by blood pressure measurements of the routine follow-ups. We extracted the blood pressure data from the Residence Health Record System, which recorded the SBP and DBP values measured in the annual health examinations and the regular follow-ups of the NEPHSP participants.</p></sec><sec id="s2-5"><title>Statistical Analysis</title><p>Baseline characteristics of the participants were statistically described. The quantitative variables were described as mean and SD, while categorical variables were described as counts and percentage. The generalized estimating equation (GEE) model was used to analyze the repetitively measured blood pressure data that contained a continuous time variable [<xref ref-type="bibr" rid="ref24">24</xref>]. The GEE model was capable of analyzing numerical and categorical data that were repetitively measured [<xref ref-type="bibr" rid="ref24">24</xref>]. Both the trend and degree of the blood pressure changes were analyzed. First, the variable of time was set as the continuous variable to analyze the trend of the blood pressure changes in the GEE models. Linear trend tests were conducted to examine whether the changes in the blood pressure values with the continuous time variation were linear. The linear trend test were reflected by <italic>P</italic> for trend [<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref>]. If the changes in the blood pressure values for the continuous time variation were linear, we used the coefficients of GEE models to reflect linear trends of blood pressure changes. Second, we also set the variable of time as the categorical variable to analyze the degree of blood pressure changes in the GEE models. The baseline blood pressure values in 2022 were chosen as the reference group. All statistical analyses were carried out by R software version 4.0.4 (R Core Team). The analysis was performed with 2-tailed tests at an &#x03B1; level of .05.</p><p>The covariates were first selected based on evidence of previous studies that had proven the factors that could impact blood pressure [<xref ref-type="bibr" rid="ref27">27</xref>-<xref ref-type="bibr" rid="ref34">34</xref>]. Subsequently, we also conducted univariate analyses to confirm whether the covariates had an impact on blood pressure. The following participant characteristics were adjusted as covariates: age, sex, BMI, waist circumference, exercise engagement, alcohol drinking and smoking status, fasting plasma glucose, total cholesterol, triglycerides, low density lipoprotein, high density lipoprotein, baseline SBP and DBP values, diagnosis of cardiovascular and renal diseases, and duration since hypertension diagnosis. The results of univariate analyses and corresponding information of each covariate in the GEE models are described in <xref ref-type="supplementary-material" rid="app1">Multimedia Appendix 1</xref> and <xref ref-type="supplementary-material" rid="app2">Multimedia Appendix 2</xref>.</p></sec><sec id="s2-6"><title>Sensitivity and Stratified Analyses</title><p>A series of stratified and sensitivity analyses were conducted to identify whether the changes in blood pressure were different by subgroup. The subgroups were predefined as an older age group (&#x2265;65 years old) and younger age group (&#x003C;65 years old), a male group and female group, a CVD diagnosis group and no CVD diagnosis group, and a baseline controlled SBP group and baseline uncontrolled SBP group. We fit GEE models to assess the changes in blood pressure separately for those subgroups. We then tested the interactive effects between the time variables (continuous time variable) and the subgroup indicators using the total sample, to formally evaluate whether the changes in blood pressure differed between the subgroups.</p></sec><sec id="s2-7"><title>Ethical Considerations</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Committee on Human Research of the Jining No. 1 People&#x2019;s Hospital (2023 Ethical Approval No. KYLL-204609&#x2010;176). The need for informed consent was waived due to the retrospective nature of this study.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Baseline Characteristics</title><p>The baseline characteristics are accessible in <xref ref-type="table" rid="table1">Table 1</xref>. A total of 516,777 participants were involved in this study. The mean age was 68.59 (SD 9.57) years, 58.56% (n=302,109) of the participants were female, and 66.94% (n=345,923) of the participants were over 65 years old. The mean values for baseline SBP and DBP were 157.12 (SD 19.88) mm Hg and 85.11 (SD 11.79) mm Hg, respectively. The mean values of baseline SBP were above the normal criteria [<xref ref-type="bibr" rid="ref19">19</xref>]. The control rates of baseline SBP and DBP were 39.79% (205,630/516,777) and 69.21% (357,685/516,777), respectively.</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Baseline characteristics.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Characteristics</td><td align="left" valign="bottom">Values</td></tr></thead><tbody><tr><td align="left" valign="top">Age (years), mean (SD)</td><td align="left" valign="top">68.39 (9.57)</td></tr><tr><td align="left" valign="top" colspan="2">Sex, n/N (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Male</td><td align="left" valign="top">214,668/516,777 (41.54)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Female</td><td align="left" valign="top">302,109/516,777 (58.56)</td></tr><tr><td align="left" valign="top">DBP<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup> (mm Hg), mean (SD)</td><td align="left" valign="top">85.11 (11.79)</td></tr><tr><td align="left" valign="top">DBP control rate, n/N (%)</td><td align="left" valign="top">357685/516,777 (69.21)</td></tr><tr><td align="left" valign="top">Cardiovascular disease diagnosis, n/N (%)</td><td align="left" valign="top">124409/516,777 (24.07)</td></tr><tr><td align="left" valign="top" colspan="2">SBP<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup> (mm Hg), mean (SD)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>All participants</td><td align="left" valign="top">147.12 (19.88)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Older participants</td><td align="left" valign="top">149.81 (20.37)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Younger participants</td><td align="left" valign="top">141.67 (17.64)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Participants with cardiovascular disease</td><td align="left" valign="top">149.14 (18.48)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Participants without cardiovascular disease</td><td align="left" valign="top">144.47 (20.02)</td></tr><tr><td align="left" valign="top" colspan="2">SBP control rate, n/N (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>All participants</td><td align="left" valign="top">205,630/516,777 (39.79)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Older participants</td><td align="left" valign="top">114,649/345,923 (33.14)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Younger participants</td><td align="left" valign="top">90,981/170,854 (53.25)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Participants with cardiovascular disease</td><td align="left" valign="top">48,552/124,409 (39.02)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x2003;Participants without cardiovascular disease</named-content></td><td align="left" valign="top">157,078/392,368 (40.03)</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>DBP: diastolic blood pressure.</p></fn><fn id="table1fn2"><p><sup>b</sup>SBP: systolic blood pressure.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Changes in SBP Control</title><p>The changes in SBP control are described in <xref ref-type="fig" rid="figure3">Figure 3</xref>. The SBP values had a linear change trend with continuous time variation (&#x03B2; coefficient=&#x2212;1.85, 95% CI &#x2212;1.86 to &#x2212;1.93; <italic>P</italic>&#x003C;.001).</p><fig position="float" id="figure3"><label>Figure 3.</label><caption><p>Changes in SBP control. SBP: systolic blood pressure.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v11i1e65783_fig03.png"/></fig><p>The SBP values showed a decreasing trend (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="figure3">Figure 3</xref>). Compared to baseline, SBP decreased in each quarter by 5.06 mm Hg, 6.69 mm Hg, 10.60 mm Hg, and 6.63 mm Hg (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Slopes of the blood pressure changes from baseline to the fourth follow-up.</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Variable</td><td align="left" valign="bottom" colspan="2">&#x03B2; coefficient (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">SBP<sup><xref ref-type="table-fn" rid="table2fn1">a</xref></sup></td><td align="left" valign="top" colspan="2">&#x2212;1.85 (&#x2212;1.86 to &#x2212;1.93)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">SBP control rate</td><td align="left" valign="top" colspan="2">0.185 (0.183-0.187)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">DBP<sup><xref ref-type="table-fn" rid="table2fn2">b</xref></sup></td><td align="left" valign="top" colspan="2">&#x2212;0.77 (&#x2212;0.78 to &#x2212;0.76)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">DBP control rate</td><td align="left" valign="top" colspan="2">0.169 (0.166-0.171)</td><td align="left" valign="top">&#x003C;.001</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>SBP: systolic blood pressure.</p></fn><fn id="table2fn2"><p><sup>b</sup>DBP: diastolic blood pressure.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" position="float"><label>Table 3.</label><caption><p>Degree of change in systolic blood pressure (SBP) control.</p></caption><table id="table3" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Appointment</td><td align="left" valign="bottom" colspan="2">SBP</td><td align="left" valign="bottom" colspan="2">SBP control rate</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">&#x03B2; coefficient (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value</td><td align="left" valign="bottom">&#x03B2; coefficient (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">Follow-up 1</td><td align="left" valign="top">&#x2212;5.00 (&#x2212;5.11 to &#x2212;5.00)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">0.18 (0.183-0.187)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Follow-up 2</td><td align="left" valign="top">&#x2212;6.69 (&#x2212;6.74 to &#x2212;6.63)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">0.60 (0.59-0.61)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Follow-up 3</td><td align="left" valign="top">&#x2212;10.60 (&#x2212;10.54 to &#x2212;10.63)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">0.76 (0.75-0.77)</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Follow-up &#x200C;4</td><td align="left" valign="top">&#x2212;6.63 (&#x2212;6.68 to &#x2212;6.57)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">1.08 (1.07-1.09)</td><td align="left" valign="top">&#x003C;.001</td></tr></tbody></table></table-wrap><p>SBP control rates for the NEPHSP participants showed an increasing trend (<xref ref-type="fig" rid="figure3">Figure 3</xref>, <xref ref-type="table" rid="table2">Table 2</xref>). Compared to baseline, SBP control rates increased in each quarter to 53.12% (274,493/516,777), 56.61% (292,537/516,777), 63.4% (327,648/516,777), and 55.09% (284,711/516,777; <xref ref-type="table" rid="table2">Table 3</xref>).</p></sec><sec id="s3-3"><title>Changes in DBP Control</title><p>The changes in DBP control are described in <xref ref-type="fig" rid="figure4">Figure 4</xref>. The DBP values had a linear trend with continuous time variation (&#x03B2; coefficient=&#x2212;1.85, 95% CI &#x2212;1.86 to &#x2212;1.93; <italic>P</italic>&#x003C;.001). The DBP values of the NEPHSP participants showed a decreasing trend (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="figure4">Figure 4</xref>). Compared to baseline DBP, DBP decreased in each quarter by 1.75 mm Hg, 2.64 mm Hg, 4.20 mm Hg, and 2.64 mm Hg (<xref ref-type="table" rid="table4">Table 4</xref>).</p><fig position="float" id="figure4"><label>Figure 4.</label><caption><p>Changes in DBP control. DBP: diastolic blood pressure.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v11i1e65783_fig04.png"/></fig><table-wrap id="t4" position="float"><label>Table 4.</label><caption><p>Degree of change in diastolic blood pressure (DBP) control.</p></caption><table id="table4" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Appointment</td><td align="left" valign="bottom" colspan="2">DBP</td><td align="left" valign="bottom" colspan="2">DBP control rate</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">&#x03B2; coefficient (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value</td><td align="left" valign="bottom">&#x03B2; coefficient (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">Follow-up 1</td><td align="left" valign="top">&#x2212;1.75 (&#x2212;1.79 to &#x2212;1.72)</td><td align="char" char="." valign="top">&#x003C;.001</td><td align="char" char="." valign="top">0.62 (0.61-0.63)</td><td align="char" char="." valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Follow-up 2</td><td align="left" valign="top">&#x2212;2.64 (&#x2212;2.68 to &#x2212;2.61)</td><td align="char" char="." valign="top">&#x003C;.001</td><td align="char" char="." valign="top">0.67 (0.66-0.68)</td><td align="char" char="." valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Follow-up 3</td><td align="left" valign="top">&#x2212;4.20 (&#x2212;4.63 to &#x2212;4.16)</td><td align="char" char="." valign="top">.01</td><td align="char" char="." valign="top">0.89 (0.88-0.90)</td><td align="char" char="." valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Follow-up&#x200C; 4</td><td align="left" valign="top">&#x2212;2.64 (&#x2212;2.68 to &#x2212;2.61)</td><td align="char" char="." valign="top">&#x003C;.001</td><td align="char" char="." valign="top">0.61 (0.60-0.62)</td><td align="char" char="." valign="top">&#x003C;.001</td></tr></tbody></table></table-wrap><p>DBP control rates for the NEPHSP participants showed an increasing trend (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="figure4">Figure 4</xref>). Compared to baseline, DBP control rates increased in each quarter to 78.11% (403,641/516,777), 80.32% (415,062/516,777), 83.17% (429,829/516,777), and 79.47% (410,662/516,777; <xref ref-type="table" rid="table4">Table 4</xref>).</p></sec><sec id="s3-4"><title>Sensitivity and Stratified Analyses</title><p>Our sensitivity analysis stratified by the predefined subgroups showed that a decrease in blood pressure and an increase in blood pressure control rates were consistent across subgroups of age, sex, and a diagnosis of baseline CVD. The parameters of the sensitivity analysis are accessible in <xref ref-type="supplementary-material" rid="app3">Multimedia Appendix 3</xref>. The changes in SBP were converse between the baseline controlled SBP and uncontrolled SBP groups. The baseline controlled SBP group had an increased control of their SBP, while the baseline uncontrolled SBP group had a decreased control of their SBP. The SBP control rates decreased in the baseline controlled SBP group, while the SBP control rates increased in the baseline uncontrolled SBP group.</p><p>The changes in SBP control in the older and younger age groups are described in <xref ref-type="fig" rid="figure5">Figure 5</xref>. Compared with younger age group, the older age group showed a larger decrease in SBP and a larger increase in SBP control rates. The SBP of the older age group were higher than the younger age group. The SBP control rates of the older age group were significantly lower than the younger age group (<italic>P</italic>&#x003C;.001).</p><fig position="float" id="figure5"><label>Figure 5.</label><caption><p>Systolic blood pressure control of the age groups.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v11i1e65783_fig05.png"/></fig><p>The changes in SBP control of the participants with and without CVD were described in <xref ref-type="fig" rid="figure6">Figure 6</xref>. The participants with CVD had a smaller decrease in SBP and smaller increase in SBP control rates than the participants without CVD. The SBP control rates of the participants with CVD were significantly lower than the participants without CVD (<italic>P</italic>&#x003C;.001).</p><fig position="float" id="figure6"><label>Figure 6.</label><caption><p>Systolic blood pressure control of the cardiovascular disease group.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="publichealth_v11i1e65783_fig06.png"/></fig><p>The stratified analysis by sex demonstrated that the decrease in SBP values and the increase in SBP control rates were greater in the female group than in male group; however, the differences were relatively small.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>To our knowledge, this is the first study that longitudinally explored effect of the NEPHSP on blood pressure control. The study findings demonstrated that the NEPHSP was effective for improving SBP and DBP control. The NEPHSP decreased the values of SBP and DBP and increased the control rates of SBP and DBP.</p><p>The routine follow-up that monitored blood pressure and the individualized interventions of the NEPHSP might contribute to the improvement of SBP and DBP control. The routine follow-ups generated clinically crucial data that could recognize prioritization of the participant subgroups who had poorly controlled blood pressures [<xref ref-type="bibr" rid="ref35">35</xref>]. Previous studies also reported that the regular population review that enables the formulation of customized interventions for improving blood pressure control is an effective strategy for hypertension management [<xref ref-type="bibr" rid="ref35">35</xref>-<xref ref-type="bibr" rid="ref48">48</xref>]. Individualized interventions were formulated according to the evaluations of routine follow-ups to identify appropriate strategies to improve blood pressure control in participants with poorly controlled blood pressure [<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref47">47</xref>].</p><p>Although the NEPHSP improved the control of blood pressure, the mean values of SBP were still slightly higher than the normal criteria. This might be caused by therapeutic inertia [<xref ref-type="bibr" rid="ref33">33</xref>]. Therapeutic inertia was defined as a failure of health care professionals to initiate or intensify treatment appropriately during visits [<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref49">49</xref>]. Previous research demonstrated that the failure to appropriately initiate or intensify treatment was introduced by the perspective of health care professionals that near-target blood pressures were acceptable and the overconcern about adverse effects caused by treatment intensification [<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref50">50</xref>,<xref ref-type="bibr" rid="ref51">51</xref>]. Because of the doctor-related factors leading to therapeutic inertia, participants with near-target blood pressures might not accept intensification of antihypertensive treatments, which could contribute to the slightly higher values of blood pressure [<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref50">50</xref>,<xref ref-type="bibr" rid="ref51">51</xref>]. Although therapeutic inertia is associated with poor blood pressure control and cardiovascular events, therapeutic inertia is common in hypertension management in primary care settings [<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref51">51</xref>]. Given this situation, interventions for handling therapeutic inertia are important for improving hypertension management in primary care settings [<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref51">51</xref>]. However, in terms of the NEPHSP, no component for tackling therapeutic inertia were embedded. The relevant components addressing therapeutic inertia can be considered for inclusion in the NEPHSP [<xref ref-type="bibr" rid="ref33">33</xref>].</p><p>The subgroup analysis showed that the older participants had greater blood pressure improvement compared to the younger participants. This finding might be relevant to the referral mechanism of the NEPHSP. Compared with younger patients with hypertension, older patients with hypertension have more complex health conditions, such as frailty, comorbidities, and polypharmacy [<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref52">52</xref>-<xref ref-type="bibr" rid="ref58">58</xref>]. These complex health conditions can introduce challenges for blood pressure control in primary care settings, which are positively associated with poor blood pressure control [<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref52">52</xref>-<xref ref-type="bibr" rid="ref58">58</xref>]. To improve poor blood pressure control in older patients with complex health conditions in primary care settings, a referral mechanism to superior medical institutions is important [<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref57">57</xref>-<xref ref-type="bibr" rid="ref59">59</xref>]. In terms of the NEPHSP, the older participants with complex health conditions and poor blood pressure control were recognized via the regular follow-up evaluations. Based on the health condition evaluations of the regular follow-ups, the older participants could accept more referrals to superior medical institutions than the younger participants. Through the referral to superior medical institutions, the older participants could receive more intensive antihypertensive treatments than the treatments in primary care settings [<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref57">57</xref>-<xref ref-type="bibr" rid="ref59">59</xref>]. Because of the intensive antihypertensive treatments provided in superior medical institutions, the older participants had more blood pressure control improvement than the younger participants [<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref57">57</xref>-<xref ref-type="bibr" rid="ref59">59</xref>].</p><p>Although older participants had a greater improvement in blood pressure control than younger participants, the SBP of the older participants were still higher than the younger participants. Moreover, the SBP control rates for the older participants were significantly lower than the younger participants. These study findings might be associated with concerns about adverse events caused by blood pressure&#x2013;lowering pharmacotherapy [<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref45">45</xref>-<xref ref-type="bibr" rid="ref58">58</xref>]. However, previous robust research evidence demonstrated that decreasing the blood pressures of older adults to normal range is safe and effective for reducing risks of cardiovascular events [<xref ref-type="bibr" rid="ref59">59</xref>,<xref ref-type="bibr" rid="ref60">60</xref>]. Consequently, older people with hypertension should have a similar attitude toward blood pressure control as younger people with hypertension [<xref ref-type="bibr" rid="ref59">59</xref>,<xref ref-type="bibr" rid="ref60">60</xref>]. Given this situation, strategies to intensify blood pressure control in older participants engaging in the NEPHSP are necessary [<xref ref-type="bibr" rid="ref59">59</xref>,<xref ref-type="bibr" rid="ref60">60</xref>].</p><p>The improvement in the blood pressure control for the participants with CVD was less than the participants without CVD, while blood pressure control for people with hypertension and CVD needs to be more intensive than people with hypertension but without CVD [<xref ref-type="bibr" rid="ref60">60</xref>]. Similar to the older participants, the patients with hypertension with CVD also required more referrals to superior medical institutions to achieve optimal blood pressure control [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. Compared to patients with hypertension without CVD, the patients with CVD demand more intensive blood pressure control to prevent cardiovascular events, and blood pressure control in patients with hypertension and CVD is challenging in primary care settings [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. The main challenges are potential adverse drug effects caused by polypharmacy and emergent cardiovascular events caused by intensive antihypertensive treatments [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. Given this situation, referral to superior medical institutions is necessary for patients with hypertension and CVD to achieve optimal blood pressure control via intensive and safe antihypertensive treatments [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>].</p><p>Although the NEPHSP had the algorithm to evaluate health conditions of the participants with comorbidities and subsequent referral mechanism to superior medical settings, the improvement of blood pressure control in the participants with CVD was still less than the participants without CVD. The lesser improvement in blood pressure control in the participants with CVD could be caused by the health evaluations of the regular follow-ups. The health condition evaluations might fail to accurately assess the health conditions of the participants with CVD, as the evaluations did not have systematic tools such as checklists, which could lead to failure to refer the participants who needed referral [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. Furthermore, no explicit criteria for referral of participants with CVD were predefined, which could lead to confusion for the primary health care professionals when making the decisions on referral [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. Given that the blood pressure control in people with hypertension and CVD needs to be more intensive than people without CVD, strategies for intensifying blood pressure control in the NEPHSP participants with CVD should be considered [<xref ref-type="bibr" rid="ref61">61</xref>-<xref ref-type="bibr" rid="ref66">66</xref>].</p><p>The subgroup analysis showed that the participants with controlled SBP at baseline had an increase in SBP and a decrease in SBP control rates, which were converse to the SBP results of all study participants. These results could be associated with the health evaluation algorithm of the regular follow-ups of the NEPHSP. According to the health evaluation algorithm, the participants who had controlled blood pressures that were evaluated in the regular follow-ups would not accept specific interventions. Because specific interventions were not provided, the participants with controlled SBP at baseline could have an increase in SBP and a decrease in SBP control rates. Although SBP of the participants was controlled at baseline, the increase of SBP values within the normal range could also increase CVD events [<xref ref-type="bibr" rid="ref58">58</xref>]. Given this situation, the health evaluation algorithm and interventions of the NEPHSP for the participants with controlled SBP at baseline were suggested to be reformulated [<xref ref-type="bibr" rid="ref58">58</xref>-<xref ref-type="bibr" rid="ref61">61</xref>].</p><p>Blood lipid and glucose control could impact hypertension management. Previous studies reported that the triglyceride-glucose index (TyG), which is calculated by multiplying fasting triglyceride by fasting glucose, had a positive relationship with blood pressure control [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref61">61</xref>,<xref ref-type="bibr" rid="ref62">62</xref>]. The increase of the TyG could contribute to poor blood pressures control [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref61">61</xref>,<xref ref-type="bibr" rid="ref63">63</xref>]. A linear dose-response relationship between changes in the TyG and the change in blood pressure was identified [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref>]. To achieve optimal blood pressure control, blood lipid and glucose should be concurrently managed in people with hypertension [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref>]. However, in terms of the NEPHSP, no treatment targets for blood lipid and glucose were predefined for the study participants, which might cause ignorance toward blood lipid and glucose control. The ignorance of blood lipid and glucose control might cause a high TyG, which could contribute to the near-target blood pressure levels in this study [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref>]. Given this situation, further studies are required to confirm whether blood lipid and glucose control impact blood pressure control of the NEPHSP participants, in order to clarify the target for improving blood pressure control in this population.</p></sec><sec id="s4-2"><title>Limitations</title><p>This study had several limitations. Although the effects of the NEPHSP on blood pressure control were modest, this study could not confirm the factors impacting blood pressure control of the NEPHSP. The group divisions for subgroup analysis were general and not explicit. Further studies that include a gradient group division to explore factors impacting hypertension control of NEPHSP are needed. Randomization for group division was not applied in the subgroup analysis, which could lead to an uneven distribution of confounding factors. Further studies that use randomization or matched group division are need to confirm the factors impacting hypertension control of the NEPHSP. This study explored baseline characteristics that could impact hypertension control of the NEPHSP, and future studies exploring the impact of the factor trajectories on hypertension control are needed. In addition, this study evaluated NEPHSP in a pilot city, and further nationwide studies are needed.</p><p>The blood pressure data in this study were the clinical records obtained from routine blood pressure measurements that were conducted via the Riva-Rocci and Korotkoff techniques [<xref ref-type="bibr" rid="ref64">64</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. The Riva-Rocci and Korotkoff techniques are still considered a cornerstone in evaluation of blood pressure levels in clinical trials [<xref ref-type="bibr" rid="ref64">64</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. However, the techniques have limitations, including that they can provide only a limited number of blood pressure values and can not reflect blood pressure fluctuations over 24 hours [<xref ref-type="bibr" rid="ref64">64</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. As a result, potential influences of blood pressure fluctuations over 24 hours in our study findings were uncertain [<xref ref-type="bibr" rid="ref64">64</xref>-<xref ref-type="bibr" rid="ref66">66</xref>]. Further studies that use advanced devices such as ambulatory blood pressure monitoring to explore impacts of 24-hour blood pressure fluctuations on effects of the NEPHSP on blood pressure control are required. Despite the uncertainty of impacts of 24-hour blood pressure fluctuations, our study findings also provide preliminary evidence for the control of blood pressure by the NEPHSP. First, our study was conducted at population level. The large scale of the study participants might reduce the impact of 24-hour blood pressure fluctuations on the changes in blood pressure levels to some degree. Second, the follow-up time was one year for this study, which could offset the impact of blood pressure fluctuations over 24 hours.</p><p>This study was designed as a self-controlled longitudinal study. We compared blood pressure levels before the participants accepted health services from the NEPHSP versus after accepting the health services. The changes in blood pressure levels could preliminarily reflect the effect of the NEPHSP on blood pressure control for the participants with hypertension. However, the data monitoring blood pressure changes were only available for the NEPHSP participants and were inaccessible for people with hypertension who did not register with the NEPHSP. Because of the inaccessibility of blood pressure monitoring data for this population, this study was unable to compare blood pressure control between the NEPHSP participants and people who did not register with the NEPHSP. Given this situation, further cohort and control trials are required to confirm advantages of the NEPHSP.</p></sec><sec id="s4-3"><title>Conclusion</title><p>The NEPHSP was effective for improving blood pressure control of Chinese people with hypertension. However, the SBP of the study participants was near-target, which could imply therapy inertia in the NEPHSP participants. A suggested strategy to tackle potential therapy inertia was to intensify blood pressure control of the NEPHSP. The effects of the NEPHSP on blood pressure control in older participants and participants with CVD were modest. Embedding intensive treatment modules into the NEPHSP was suggested to improve blood pressure control of older participants and participants with CVD. Further studies confirming effects of the NEPHSP on blood pressure control for people with specific characteristics, such as older age and comorbidities, are required.</p></sec></sec></body><back><ack><p>We are grateful to all the staff who participated in this research survey.</p></ack><notes><sec><title>Data Availability</title><p>The data that support the findings of this study are available on reasonable request from the corresponding author. The data are not publicly available due to their containing information that could compromise the privacy of the participants.</p></sec></notes><fn-group><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">CVD</term><def><p>cardiovascular disease</p></def></def-item><def-item><term id="abb2">DBP</term><def><p>diastolic blood pressure</p></def></def-item><def-item><term id="abb3">GEE</term><def><p>generalized estimating equation</p></def></def-item><def-item><term id="abb4">NEPHSP</term><def><p>National Essential Public Health Service Package</p></def></def-item><def-item><term id="abb5">SBP</term><def><p>systolic blood pressure</p></def></def-item><def-item><term id="abb6">TyG</term><def><p> triglyceride-glucose index</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><collab>GBD 2019 Viewpoint Collaborators</collab></person-group><article-title>Five insights from the Global Burden of Disease Study 2019</article-title><source>Lancet</source><year>2020</year><month>10</month><day>17</day><volume>396</volume><issue>10258</issue><fpage>1135</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31404-5</pub-id><pub-id pub-id-type="medline">33069324</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><collab>GBD 2019 Diseases and Injuries Collaborators</collab></person-group><article-title>Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet</source><year>2020</year><month>10</month><day>17</day><volume>396</volume><issue>10258</issue><fpage>1204</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30925-9</pub-id><pub-id pub-id-type="medline">33069326</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewington</surname><given-names>S</given-names> </name><name name-style="western"><surname>Lacey</surname><given-names>B</given-names> </name><name name-style="western"><surname>Clarke</surname><given-names>R</given-names> </name><etal/></person-group><article-title>The burden of hypertension and associated risk for cardiovascular mortality in China</article-title><source>JAMA Intern Med</source><year>2016</year><month>04</month><volume>176</volume><issue>4</issue><fpage>524</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2016.0190</pub-id><pub-id pub-id-type="medline">26975032</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><collab>GBD 2019 Risk Factors Collaborators</collab></person-group><article-title>Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet</source><year>2020</year><month>10</month><day>17</day><volume>396</volume><issue>10258</issue><fpage>1223</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30752-2</pub-id><pub-id pub-id-type="medline">33069327</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>GA</given-names> </name><name name-style="western"><surname>Mensah</surname><given-names>GA</given-names> </name><name name-style="western"><surname>Johnson</surname><given-names>CO</given-names> </name><etal/></person-group><article-title>Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019</article-title><source>EClinMed</source><year>2023</year><volume>59</volume><fpage>101956</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101956</pub-id><pub-id pub-id-type="medline">37125402</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>ZJ</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Ge</surname><given-names>JP</given-names> </name><etal/></person-group><article-title>Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study</article-title><source>Eur Heart J</source><year>2012</year><month>01</month><volume>33</volume><issue>2</issue><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr205</pub-id><pub-id pub-id-type="medline">21719451</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names> </name><name name-style="western"><surname>Lv</surname><given-names>J</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>F</given-names> </name><etal/></person-group><article-title>Hypertension burden and control in mainland China: analysis of nationwide data 2003-2012</article-title><source>Int J Cardiol</source><year>2015</year><month>04</month><day>1</day><volume>184</volume><fpage>637</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.03.045</pub-id><pub-id pub-id-type="medline">25771229</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>XL</given-names> </name><name name-style="western"><surname>Pang</surname><given-names>M</given-names> </name><name name-style="western"><surname>Beard</surname><given-names>J</given-names> </name></person-group><article-title>Health system strengthening and hypertension awareness, treatment and control: data from the China Health and Retirement Longitudinal Study</article-title><source>Bull World Health Organ</source><year>2014</year><month>01</month><day>1</day><volume>92</volume><issue>1</issue><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.2471/BLT.13.124495</pub-id><pub-id pub-id-type="medline">24391298</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J</given-names> </name><name name-style="western"><surname>Gu</surname><given-names>D</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Premature deaths attributable to blood pressure in China: a prospective cohort study</article-title><source>Lancet</source><year>2009</year><month>11</month><day>21</day><volume>374</volume><issue>9703</issue><fpage>1765</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61199-5</pub-id><pub-id pub-id-type="medline">19811816</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names> </name></person-group><article-title>Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2013</year><month>06</month><day>8</day><volume>381</volume><issue>9882</issue><fpage>1987</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61097-1.</pub-id><pub-id pub-id-type="medline">23746901</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>F</given-names> </name><name name-style="western"><surname>Liu</surname><given-names>L</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>H</given-names> </name><collab>China National Survey of Chronic Kidney Disease Working Group</collab></person-group><article-title>Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey</article-title><source>Am J Hypertens</source><year>2014</year><month>11</month><volume>27</volume><issue>11</issue><fpage>1355</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1093/ajh/hpu053</pub-id><pub-id pub-id-type="medline">24698853</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names> </name><name name-style="western"><surname>Gu</surname><given-names>H</given-names> </name><name name-style="western"><surname>Teo</surname><given-names>KK</given-names> </name><etal/></person-group><article-title>Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47&#x200A;000 people from China</article-title><source>J Hypertens</source><year>2016</year><month>01</month><volume>34</volume><issue>1</issue><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000000745</pub-id><pub-id pub-id-type="medline">26630211</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>X</given-names> </name><etal/></person-group><article-title>Prevalence, awareness, treatment, and control of hypertension in China: data from 17 million adults in a population-based screening study (China PEACE Million Persons Project)</article-title><source>Lancet</source><year>2017</year><month>12</month><day>9</day><volume>390</volume><issue>10112</issue><fpage>2549</fpage><lpage>2558</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)32478-9</pub-id><pub-id pub-id-type="medline">29102084</pub-id></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>L</given-names> </name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>X</given-names> </name></person-group><article-title>National essential public health services programs over the past decade research report two: progress and achievements of the implementation of National Essential Public Health Services Programs over the past decade</article-title><source>Chin Gen Pract</source><year>2022</year><volume>25</volume><fpage>3209</fpage><lpage>3220</lpage><pub-id pub-id-type="doi">10.12114/j.issn.1007-9572.2022.0407</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>G</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>D</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>L</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>J</given-names> </name></person-group><article-title>Experiences and challenges of implementing universal health coverage with China&#x2019;s National Basic Public Health Service Program: literature review, regression analysis, and insider interviews</article-title><source>JMIR Public Health Surveill</source><year>2022</year><volume>8</volume><issue>7</issue><fpage>e31289</fpage><pub-id pub-id-type="doi">10.2196/31289</pub-id><pub-id pub-id-type="medline">35867386</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names> </name><name name-style="western"><surname>Lu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Hu</surname><given-names>S</given-names> </name><etal/></person-group><article-title>The primary health-care system in China</article-title><source>Lancet</source><year>2017</year><month>12</month><day>9</day><volume>390</volume><issue>10112</issue><fpage>2584</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33109-4</pub-id><pub-id pub-id-type="medline">29231837</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names> </name><name name-style="western"><surname>Krumholz</surname><given-names>HM</given-names> </name><name name-style="western"><surname>Yip</surname><given-names>W</given-names> </name><etal/></person-group><article-title>Quality of primary health care in China: challenges and recommendations</article-title><source>Lancet</source><year>2020</year><month>06</month><day>6</day><volume>395</volume><issue>10239</issue><fpage>1802</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30122-7</pub-id><pub-id pub-id-type="medline">32505251</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>S</given-names> </name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names> </name><name name-style="western"><surname>Meng</surname><given-names>R</given-names> </name><etal/></person-group><article-title>Factors associated with the uptake of national essential public health service package for hypertension and type-2 diabetes management in China&#x2019;s primary health care system: a mixed-methods study</article-title><source>Lancet Reg Health West Pac</source><year>2023</year><month>02</month><volume>31</volume><fpage>100664</fpage><pub-id pub-id-type="doi">10.1016/j.lanwpc.2022.100664</pub-id><pub-id pub-id-type="medline">36879777</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Colditz</surname><given-names>GA</given-names> </name></person-group><article-title>Optimal design of longitudinal data analysis using generalized estimating equation models</article-title><source>Biom J</source><year>2017</year><month>03</month><volume>59</volume><issue>2</issue><fpage>315</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1002/bimj.201600107</pub-id><pub-id pub-id-type="medline">27878852</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>AB</given-names> </name></person-group><article-title>An overview of the design, implementation, and analyses of longitudinal studies on aging</article-title><source>J Am Geriatr Soc</source><year>2010</year><month>10</month><volume>58 Suppl 2</volume><issue>Suppl 2</issue><fpage>S287</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2010.02916.x</pub-id><pub-id pub-id-type="medline">21029055</pub-id></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneeweiss</surname><given-names>S</given-names> </name><name name-style="western"><surname>Rassen</surname><given-names>JA</given-names> </name><name name-style="western"><surname>Brown</surname><given-names>JS</given-names> </name><etal/></person-group><article-title>Graphical depiction of longitudinal study designs in health care databases</article-title><source>Ann Intern Med</source><year>2019</year><month>03</month><day>19</day><volume>170</volume><issue>6</issue><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.7326/M18-3079</pub-id><pub-id pub-id-type="medline">30856654</pub-id></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hund</surname><given-names>H</given-names> </name><name name-style="western"><surname>Gerth</surname><given-names>S</given-names> </name><name name-style="western"><surname>Lossnitzer</surname><given-names>D</given-names> </name><name name-style="western"><surname>Fegeler</surname><given-names>C</given-names> </name></person-group><article-title>Longitudinal data driven study design</article-title><source>Stud Health Technol Inform</source><year>2014</year><volume>205</volume><issue>373-7</issue><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="medline">25160209</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JG</given-names> </name><name name-style="western"><surname>Chia</surname><given-names>YC</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names> </name><etal/></person-group><article-title>What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?</article-title><source>J Clin Hypertens (Greenwich)</source><year>2020</year><month>03</month><volume>22</volume><issue>3</issue><fpage>363</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1111/jch.13803</pub-id><pub-id pub-id-type="medline">31955513</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Pan</surname><given-names>J</given-names> </name></person-group><article-title>Penalized joint generalized estimating equations for longitudinal binary data</article-title><source>Biom J</source><year>2022</year><month>01</month><volume>64</volume><issue>1</issue><fpage>57</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/bimj.202000336</pub-id><pub-id pub-id-type="medline">34587284</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>DH</given-names> </name><name name-style="western"><surname>Keum</surname><given-names>N</given-names> </name><name name-style="western"><surname>Hu</surname><given-names>FB</given-names> </name><etal/></person-group><article-title>Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study</article-title><source>BMJ</source><year>2018</year><month>07</month><day>3</day><volume>362</volume><fpage>k2575</fpage><pub-id pub-id-type="doi">10.1136/bmj.k2575</pub-id><pub-id pub-id-type="medline">29970408</pub-id></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>C</given-names> </name><name name-style="western"><surname>Lu</surname><given-names>L</given-names> </name><name name-style="western"><surname>Shikany</surname><given-names>JM</given-names> </name><name name-style="western"><surname>D&#x2019;Alton</surname><given-names>ME</given-names> </name><name name-style="western"><surname>Kahe</surname><given-names>K</given-names> </name></person-group><article-title>Folate, vitamin B6, and vitamin B12 status in association with metabolic syndrome incidence</article-title><source>JAMA Netw Open</source><year>2023</year><month>01</month><day>3</day><volume>6</volume><issue>1</issue><fpage>e2250621</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.50621</pub-id><pub-id pub-id-type="medline">36630134</pub-id></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names> </name><name name-style="western"><surname>He</surname><given-names>K</given-names> </name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names> </name><etal/></person-group><article-title>Association of body mass index and waist circumference with high blood pressure in older adults</article-title><source>BMC Geriatr</source><year>2021</year><month>04</month><day>19</day><volume>21</volume><issue>1</issue><fpage>260</fpage><pub-id pub-id-type="doi">10.1186/s12877-021-02154-5</pub-id><pub-id pub-id-type="medline">33874889</pub-id></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowling</surname><given-names>CB</given-names> </name><name name-style="western"><surname>Sloane</surname><given-names>R</given-names> </name><name name-style="western"><surname>Pieper</surname><given-names>C</given-names> </name><etal/></person-group><article-title>Association of sustained blood pressure control with multimorbidity progression among older adults</article-title><source>J Am Geriatr Soc</source><year>2020</year><month>09</month><volume>68</volume><issue>9</issue><fpage>2059</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.1111/jgs.16558</pub-id><pub-id pub-id-type="medline">32501546</pub-id></nlm-citation></ref><ref id="ref29"><label>29</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karmali</surname><given-names>KN</given-names> </name><name name-style="western"><surname>Lloyd-Jones</surname><given-names>DM</given-names> </name><name name-style="western"><surname>van der Leeuw</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data</article-title><source>PLoS Med</source><year>2018</year><month>03</month><volume>15</volume><issue>3</issue><fpage>e1002538</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1002538</pub-id><pub-id pub-id-type="medline">29558462</pub-id></nlm-citation></ref><ref id="ref30"><label>30</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czernichow</surname><given-names>S</given-names> </name><name name-style="western"><surname>Castetbon</surname><given-names>K</given-names> </name><name name-style="western"><surname>Salanave</surname><given-names>B</given-names> </name><etal/></person-group><article-title>Determinants of blood pressure treatment and control in obese people: evidence from the general population</article-title><source>J Hypertens</source><year>2012</year><month>12</month><volume>30</volume><issue>12</issue><fpage>2338</fpage><lpage>2344</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e3283593010</pub-id><pub-id pub-id-type="medline">23032140</pub-id></nlm-citation></ref><ref id="ref31"><label>31</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names> </name><name name-style="western"><surname>Song</surname><given-names>Y</given-names> </name><etal/></person-group><article-title>Ideal cardiovascular health index and high-normal blood pressure in elderly people: evidence based on real-world data</article-title><source>Sci Rep</source><year>2024</year><month>05</month><day>3</day><volume>14</volume><issue>1</issue><fpage>10166</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-60906-w</pub-id><pub-id pub-id-type="medline">38702348</pub-id></nlm-citation></ref><ref id="ref32"><label>32</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aljuraiban</surname><given-names>GS</given-names> </name><name name-style="western"><surname>Alharbi</surname><given-names>FJ</given-names> </name><name name-style="western"><surname>Aljohi</surname><given-names>AO</given-names> </name><etal/></person-group><article-title>Triglyceride-glucose index (TyG index) in association with blood pressure in adults: a retrospective study</article-title><source>Int J Gen Med</source><year>2024</year><volume>17</volume><fpage>3395</fpage><lpage>3402</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S469147</pub-id><pub-id pub-id-type="medline">39130487</pub-id></nlm-citation></ref><ref id="ref33"><label>33</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masoli</surname><given-names>JAH</given-names> </name><name name-style="western"><surname>Mensah</surname><given-names>E</given-names> </name><name name-style="western"><surname>Rajkumar</surname><given-names>C</given-names> </name></person-group><article-title>Age and ageing cardiovascular collection: blood pressure, coronary heart disease and heart failure</article-title><source>Age Ageing</source><year>2022</year><month>08</month><day>2</day><volume>51</volume><issue>8</issue><fpage>afac179</fpage><pub-id pub-id-type="doi">10.1093/ageing/afac179</pub-id><pub-id pub-id-type="medline">35934320</pub-id></nlm-citation></ref><ref id="ref34"><label>34</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>MCS</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>HHX</given-names> </name><name name-style="western"><surname>Cheung</surname><given-names>CSK</given-names> </name><etal/></person-group><article-title>Factors associated with multimorbidity and its link with poor blood pressure control among 223,286 hypertensive patients</article-title><source>Int J Cardiol</source><year>2014</year><month>11</month><day>15</day><volume>177</volume><issue>1</issue><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.09.021</pub-id><pub-id pub-id-type="medline">25499379</pub-id></nlm-citation></ref><ref id="ref35"><label>35</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glynn</surname><given-names>LG</given-names> </name><name name-style="western"><surname>Murphy</surname><given-names>AW</given-names> </name><name name-style="western"><surname>Smith</surname><given-names>SM</given-names> </name><name name-style="western"><surname>Schroeder</surname><given-names>K</given-names> </name><name name-style="western"><surname>Fahey</surname><given-names>T</given-names> </name></person-group><article-title>Interventions used to improve control of blood pressure in patients with hypertension</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><month>03</month><day>17</day><volume>17</volume><issue>3</issue><fpage>CD005182</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD005182.pub4</pub-id><pub-id pub-id-type="medline">20238338</pub-id></nlm-citation></ref><ref id="ref36"><label>36</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaffe</surname><given-names>MG</given-names> </name><name name-style="western"><surname>Lee</surname><given-names>GA</given-names> </name><name name-style="western"><surname>Young</surname><given-names>JD</given-names> </name><name name-style="western"><surname>Sidney</surname><given-names>S</given-names> </name><name name-style="western"><surname>Go</surname><given-names>AS</given-names> </name></person-group><article-title>Improved blood pressure control associated with a large-scale hypertension program</article-title><source>JAMA</source><year>2013</year><month>08</month><day>21</day><volume>310</volume><issue>7</issue><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.108769</pub-id><pub-id pub-id-type="medline">23989679</pub-id></nlm-citation></ref><ref id="ref37"><label>37</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jafar</surname><given-names>TH</given-names> </name><name name-style="western"><surname>Gandhi</surname><given-names>M</given-names> </name><name name-style="western"><surname>de Silva</surname><given-names>HA</given-names> </name><etal/></person-group><article-title>A community-based intervention for managing hypertension in rural South Asia</article-title><source>N Engl J Med</source><year>2020</year><month>02</month><day>20</day><volume>382</volume><issue>8</issue><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1911965</pub-id><pub-id pub-id-type="medline">32074419</pub-id></nlm-citation></ref><ref id="ref38"><label>38</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwalm</surname><given-names>JD</given-names> </name><name name-style="western"><surname>McCready</surname><given-names>T</given-names> </name><name name-style="western"><surname>Lopez-Jaramillo</surname><given-names>P</given-names> </name><etal/></person-group><article-title>A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial</article-title><source>Lancet</source><year>2019</year><month>10</month><day>5</day><volume>394</volume><issue>10205</issue><fpage>1231</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31949-X</pub-id><pub-id pub-id-type="medline">31488369</pub-id></nlm-citation></ref><ref id="ref39"><label>39</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>TN</given-names> </name><name name-style="western"><surname>Joseph</surname><given-names>LM</given-names> </name><name name-style="western"><surname>Geetha</surname><given-names>AV</given-names> </name><name name-style="western"><surname>Prabhakaran</surname><given-names>D</given-names> </name><name name-style="western"><surname>Jeemon</surname><given-names>P</given-names> </name></person-group><article-title>Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and meta-analysis</article-title><source>Lancet Glob Health</source><year>2019</year><month>06</month><volume>7</volume><issue>6</issue><fpage>e761</fpage><lpage>e771</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30077-4</pub-id><pub-id pub-id-type="medline">31097278</pub-id></nlm-citation></ref><ref id="ref40"><label>40</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlaich</surname><given-names>MP</given-names> </name><name name-style="western"><surname>Kiuchi</surname><given-names>MG</given-names> </name><name name-style="western"><surname>Nolde</surname><given-names>JM</given-names> </name><name name-style="western"><surname>Lugo-Gavidia</surname><given-names>LM</given-names> </name><name name-style="western"><surname>Carnagarin</surname><given-names>R</given-names> </name></person-group><article-title>Therapeutic inertia in hypertension management - status quo in primary care</article-title><source>J Hypertens</source><year>2021</year><month>06</month><day>1</day><volume>39</volume><issue>6</issue><fpage>1107</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002830</pub-id><pub-id pub-id-type="medline">33967214</pub-id></nlm-citation></ref><ref id="ref41"><label>41</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>LS</given-names> </name><name name-style="western"><surname>Branch</surname><given-names>WT</given-names> </name><name name-style="western"><surname>Cook</surname><given-names>CB</given-names> </name><etal/></person-group><article-title>Clinical inertia</article-title><source>Ann Intern Med</source><year>2001</year><month>11</month><day>6</day><volume>135</volume><issue>9</issue><fpage>825</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-135-9-200111060-00012</pub-id><pub-id pub-id-type="medline">11694107</pub-id></nlm-citation></ref><ref id="ref42"><label>42</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milman</surname><given-names>T</given-names> </name><name name-style="western"><surname>Joundi</surname><given-names>RA</given-names> </name><name name-style="western"><surname>Alotaibi</surname><given-names>NM</given-names> </name><name name-style="western"><surname>Saposnik</surname><given-names>G</given-names> </name></person-group><article-title>Clinical inertia in the pharmacological management of hypertension: a systematic review and meta-analysis</article-title><source>Medicine (Baltimore)</source><year>2018</year><month>06</month><volume>97</volume><issue>25</issue><fpage>e11121</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000011121</pub-id><pub-id pub-id-type="medline">29924011</pub-id></nlm-citation></ref><ref id="ref43"><label>43</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebeau</surname><given-names>JP</given-names> </name><name name-style="western"><surname>Cadwallader</surname><given-names>JS</given-names> </name><name name-style="western"><surname>Vaillant-Roussel</surname><given-names>H</given-names> </name><etal/></person-group><article-title>General practitioners&#x2019; justifications for therapeutic inertia in cardiovascular prevention: an empirically grounded typology</article-title><source>BMJ Open</source><year>2016</year><month>05</month><day>13</day><volume>6</volume><issue>5</issue><fpage>e010639</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2015-010639</pub-id><pub-id pub-id-type="medline">27178974</pub-id></nlm-citation></ref><ref id="ref44"><label>44</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>EA</given-names> </name><name name-style="western"><surname>Zikmund-Fisher</surname><given-names>BJ</given-names> </name><name name-style="western"><surname>Klamerus</surname><given-names>ML</given-names> </name><name name-style="western"><surname>Subramanian</surname><given-names>U</given-names> </name><name name-style="western"><surname>Hogan</surname><given-names>MM</given-names> </name><name name-style="western"><surname>Hofer</surname><given-names>TP</given-names> </name></person-group><article-title>The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure</article-title><source>Ann Intern Med</source><year>2008</year><month>05</month><day>20</day><volume>148</volume><issue>10</issue><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-148-10-200805200-00004</pub-id><pub-id pub-id-type="medline">18490685</pub-id></nlm-citation></ref><ref id="ref45"><label>45</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masoli</surname><given-names>JAH</given-names> </name><name name-style="western"><surname>Delgado</surname><given-names>J</given-names> </name><name name-style="western"><surname>Pilling</surname><given-names>L</given-names> </name><name name-style="western"><surname>Strain</surname><given-names>D</given-names> </name><name name-style="western"><surname>Melzer</surname><given-names>D</given-names> </name></person-group><article-title>Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality</article-title><source>Age Ageing</source><year>2020</year><month>08</month><day>24</day><volume>49</volume><issue>5</issue><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1093/ageing/afaa028</pub-id><pub-id pub-id-type="medline">32133525</pub-id></nlm-citation></ref><ref id="ref46"><label>46</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>C</given-names> </name><name name-style="western"><surname>Smith</surname><given-names>CD</given-names> </name><name name-style="western"><surname>Masoudi</surname><given-names>FA</given-names> </name><etal/></person-group><article-title>Decision making for older adults with multiple chronic conditions: executive summary for the American Geriatrics Society Guiding Principles on the Care of Older Adults With Multimorbidity</article-title><source>J Am Geriatr Soc</source><year>2019</year><month>04</month><volume>67</volume><issue>4</issue><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1111/jgs.15809</pub-id><pub-id pub-id-type="medline">30663782</pub-id></nlm-citation></ref><ref id="ref47"><label>47</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benetos</surname><given-names>A</given-names> </name><name name-style="western"><surname>Petrovic</surname><given-names>M</given-names> </name><name name-style="western"><surname>Strandberg</surname><given-names>T</given-names> </name></person-group><article-title>Hypertension management in older and frail older patients</article-title><source>Circ Res</source><year>2019</year><month>03</month><day>29</day><volume>124</volume><issue>7</issue><fpage>1045</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313236</pub-id><pub-id pub-id-type="medline">30920928</pub-id></nlm-citation></ref><ref id="ref48"><label>48</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anker</surname><given-names>D</given-names> </name><name name-style="western"><surname>Santos-Eggimann</surname><given-names>B</given-names> </name><name name-style="western"><surname>Zwahlen</surname><given-names>M</given-names> </name><etal/></person-group><article-title>Blood pressure control and complex health conditions in older adults: impact of recent hypertension management guidelines</article-title><source>J Hum Hypertens</source><year>2021</year><month>03</month><volume>35</volume><issue>3</issue><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/s41371-020-0334-4</pub-id><pub-id pub-id-type="medline">32346124</pub-id></nlm-citation></ref><ref id="ref49"><label>49</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowling</surname><given-names>CB</given-names> </name><name name-style="western"><surname>Lee</surname><given-names>A</given-names> </name><name name-style="western"><surname>Williamson</surname><given-names>JD</given-names> </name></person-group><article-title>Blood pressure control among older adults with hypertension: narrative review and introduction of a framework for improving care</article-title><source>Am J Hypertens</source><year>2021</year><month>04</month><day>2</day><volume>34</volume><issue>3</issue><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1093/ajh/hpab002</pub-id><pub-id pub-id-type="medline">33821943</pub-id></nlm-citation></ref><ref id="ref50"><label>50</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>WL</given-names> </name><name name-style="western"><surname>Cai</surname><given-names>J</given-names> </name></person-group><article-title>STEP to blood pressure management of elderly hypertension: evidence from Asia</article-title><source>Hypertens Res</source><year>2022</year><month>04</month><volume>45</volume><issue>4</issue><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/s41440-022-00875-7</pub-id><pub-id pub-id-type="medline">35277670</pub-id></nlm-citation></ref><ref id="ref51"><label>51</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><collab>Blood Pressure Lowering Treatment Trialists' Collaboration</collab></person-group><article-title>Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis</article-title><source>Lancet</source><year>2021</year><month>09</month><day>18</day><volume>398</volume><issue>10305</issue><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01921-8</pub-id><pub-id pub-id-type="medline">34461040</pub-id></nlm-citation></ref><ref id="ref52"><label>52</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curfman</surname><given-names>G</given-names> </name><name name-style="western"><surname>Bauchner</surname><given-names>H</given-names> </name><name name-style="western"><surname>Greenland</surname><given-names>P</given-names> </name></person-group><article-title>Treatment and control of hypertension in 2020: the need for substantial improvement</article-title><source>JAMA</source><year>2020</year><month>09</month><day>22</day><volume>324</volume><issue>12</issue><fpage>1166</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.13322</pub-id><pub-id pub-id-type="medline">32902571</pub-id></nlm-citation></ref><ref id="ref53"><label>53</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>CM</given-names> </name><name name-style="western"><surname>Darer</surname><given-names>J</given-names> </name><name name-style="western"><surname>Boult</surname><given-names>C</given-names> </name><name name-style="western"><surname>Fried</surname><given-names>LP</given-names> </name><name name-style="western"><surname>Boult</surname><given-names>L</given-names> </name><name name-style="western"><surname>Wu</surname><given-names>AW</given-names> </name></person-group><article-title>Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance</article-title><source>JAMA</source><year>2005</year><month>08</month><day>10</day><volume>294</volume><issue>6</issue><fpage>716</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1001/jama.294.6.716</pub-id><pub-id pub-id-type="medline">16091574</pub-id></nlm-citation></ref><ref id="ref54"><label>54</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valderas</surname><given-names>JM</given-names> </name><name name-style="western"><surname>Starfield</surname><given-names>B</given-names> </name><name name-style="western"><surname>Roland</surname><given-names>M</given-names> </name></person-group><article-title>Multimorbidity&#x2019;s many challenges: a research priority in the UK</article-title><source>BMJ</source><year>2007</year><month>06</month><day>2</day><volume>334</volume><issue>7604</issue><fpage>1128</fpage><pub-id pub-id-type="doi">10.1136/bmj.39226.427095.3A</pub-id><pub-id pub-id-type="medline">17540918</pub-id></nlm-citation></ref><ref id="ref55"><label>55</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennard</surname><given-names>L</given-names> </name><name name-style="western"><surname>O&#x2019;Shaughnessy</surname><given-names>KM</given-names> </name></person-group><article-title>Treating hypertension in patients with medical comorbidities</article-title><source>BMJ</source><year>2016</year><month>02</month><day>16</day><volume>352</volume><fpage>i101</fpage><pub-id pub-id-type="doi">10.1136/bmj.i101</pub-id><pub-id pub-id-type="medline">26884124</pub-id></nlm-citation></ref><ref id="ref56"><label>56</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>C</given-names> </name><name name-style="western"><surname>Dodhia</surname><given-names>H</given-names> </name><name name-style="western"><surname>Crompton</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Hypertension: a cross-sectional study of the role of multimorbidity in blood pressure control</article-title><source>BMC Fam Pract</source><year>2015</year><month>08</month><day>7</day><volume>16</volume><fpage>98</fpage><pub-id pub-id-type="doi">10.1186/s12875-015-0313-y</pub-id><pub-id pub-id-type="medline">26248616</pub-id></nlm-citation></ref><ref id="ref57"><label>57</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulsen</surname><given-names>MS</given-names> </name><name name-style="western"><surname>Andersen</surname><given-names>M</given-names> </name><name name-style="western"><surname>Thomsen</surname><given-names>JL</given-names> </name><etal/></person-group><article-title>Multimorbidity and blood pressure control in 37 651 hypertensive patients from Danish general practice</article-title><source>J Am Heart Assoc</source><year>2012</year><month>12</month><day>31</day><volume>2</volume><issue>1</issue><fpage>e004531</fpage><pub-id pub-id-type="doi">10.1161/JAHA.112.004531</pub-id><pub-id pub-id-type="medline">23525411</pub-id></nlm-citation></ref><ref id="ref58"><label>58</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messerli</surname><given-names>FH</given-names> </name><name name-style="western"><surname>Hofstetter</surname><given-names>L</given-names> </name><name name-style="western"><surname>Rimoldi</surname><given-names>SF</given-names> </name><name name-style="western"><surname>Rexhaj</surname><given-names>E</given-names> </name><name name-style="western"><surname>Bangalore</surname><given-names>S</given-names> </name></person-group><article-title>Risk factor variability and cardiovascular outcome: JACC review topic of the week</article-title><source>J Am Coll Cardiol</source><year>2019</year><month>05</month><day>28</day><volume>73</volume><issue>20</issue><fpage>2596</fpage><lpage>2603</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.02.063</pub-id><pub-id pub-id-type="medline">31118154</pub-id></nlm-citation></ref><ref id="ref59"><label>59</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehlum</surname><given-names>MH</given-names> </name><name name-style="western"><surname>Liest&#x00F8;l</surname><given-names>K</given-names> </name><name name-style="western"><surname>Kjeldsen</surname><given-names>SE</given-names> </name><etal/></person-group><article-title>Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks</article-title><source>Eur Heart J</source><year>2018</year><month>06</month><day>21</day><volume>39</volume><issue>24</issue><fpage>2243</fpage><lpage>2251</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx760</pub-id><pub-id pub-id-type="medline">29365085</pub-id></nlm-citation></ref><ref id="ref60"><label>60</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mezue</surname><given-names>K</given-names> </name><name name-style="western"><surname>Goyal</surname><given-names>A</given-names> </name><name name-style="western"><surname>Pressman</surname><given-names>GS</given-names> </name><name name-style="western"><surname>Matthew</surname><given-names>R</given-names> </name><name name-style="western"><surname>Horrow</surname><given-names>JC</given-names> </name><name name-style="western"><surname>Rangaswami</surname><given-names>J</given-names> </name></person-group><article-title>Blood pressure variability predicts adverse events and cardiovascular outcomes in SPRINT</article-title><source>J Clin Hypertens (Greenwich)</source><year>2018</year><month>09</month><volume>20</volume><issue>9</issue><fpage>1247</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1111/jch.13346</pub-id><pub-id pub-id-type="medline">29984884</pub-id></nlm-citation></ref><ref id="ref61"><label>61</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>SL</given-names> </name><name name-style="western"><surname>Wood</surname><given-names>S</given-names> </name><name name-style="western"><surname>Koshiaris</surname><given-names>C</given-names> </name><etal/></person-group><article-title>Blood pressure variability and cardiovascular disease: systematic review and meta-analysis</article-title><source>BMJ</source><year>2016</year><month>08</month><day>9</day><volume>354</volume><fpage>i4098</fpage><pub-id pub-id-type="doi">10.1136/bmj.i4098</pub-id><pub-id pub-id-type="medline">27511067</pub-id></nlm-citation></ref><ref id="ref62"><label>62</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Yang</surname><given-names>W</given-names> </name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names> </name></person-group><article-title>Association between triglyceride-glucose index and hypertension: a meta-analysis</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>644035</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.644035</pub-id><pub-id pub-id-type="medline">34136539</pub-id></nlm-citation></ref><ref id="ref63"><label>63</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>AR</given-names> </name><name name-style="western"><surname>Jin</surname><given-names>Q</given-names> </name><name name-style="western"><surname>Shen</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Fu</surname><given-names>Q</given-names> </name></person-group><article-title>Association between the risk of hypertension and triglyceride glucose index in Chinese regions: a systematic review and dose-response meta-analysis of a regional update</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1242035</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1242035</pub-id><pub-id pub-id-type="medline">37583585</pub-id></nlm-citation></ref><ref id="ref64"><label>64</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parati</surname><given-names>G</given-names> </name><name name-style="western"><surname>Bilo</surname><given-names>G</given-names> </name><name name-style="western"><surname>Mancia</surname><given-names>G</given-names> </name></person-group><article-title>Blood pressure measurement in research and in clinical practice: recent evidence</article-title><source>Curr Opin Nephrol Hypertens</source><year>2004</year><month>05</month><volume>13</volume><issue>3</issue><fpage>343</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1097/00041552-200405000-00013</pub-id><pub-id pub-id-type="medline">15073495</pub-id></nlm-citation></ref><ref id="ref65"><label>65</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sewell</surname><given-names>K</given-names> </name><name name-style="western"><surname>Halanych</surname><given-names>JH</given-names> </name><name name-style="western"><surname>Russell</surname><given-names>LB</given-names> </name><etal/></person-group><article-title>Blood pressure measurement biases in clinical settings, Alabama, 2010-2011</article-title><source>Prev Chronic Dis</source><year>2016</year><month>01</month><day>7</day><volume>13</volume><fpage>E01</fpage><pub-id pub-id-type="doi">10.5888/pcd13.150348</pub-id><pub-id pub-id-type="medline">26741995</pub-id></nlm-citation></ref><ref id="ref66"><label>66</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><collab>Atherosclerosis, Hypertension, and Obesity in the Young Committee of the American Heart Association Council on Cardiovascular Disease in the Young</collab><name name-style="western"><surname>Alpert</surname><given-names>B</given-names> </name><name name-style="western"><surname>McCrindle</surname><given-names>B</given-names> </name><etal/></person-group><article-title>Recommendations for blood pressure measurement in human and experimental animals; part 1: blood pressure measurement in humans</article-title><source>Hypertension</source><year>2006</year><month>07</month><volume>48</volume><issue>1</issue><fpage>e3</fpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000229661.06235.08</pub-id><pub-id pub-id-type="medline">16769991</pub-id></nlm-citation></ref></ref-list><app-group><supplementary-material id="app1"><label>Multimedia Appendix 1</label><p>Univariate regression analysis of covariates.</p><media xlink:href="publichealth_v11i1e65783_app1.xlsx" xlink:title="XLSX File, 11 KB"/></supplementary-material><supplementary-material id="app2"><label>Multimedia Appendix 2</label><p>Corresponding information of each covariate in the generalized estimating equation regressions.</p><media xlink:href="publichealth_v11i1e65783_app2.xlsx" xlink:title="XLSX File, 12 KB"/></supplementary-material><supplementary-material id="app3"><label>Multimedia Appendix 3</label><p>Subgroup analysis.</p><media xlink:href="publichealth_v11i1e65783_app3.xlsx" xlink:title="XLSX File, 10 KB"/></supplementary-material></app-group></back></article>